01/07/21 7:30 AMNasdaq : ATHA conferencesAthira Pharma to Present at the 39th Annual J.P. Morgan Healthcare ConferenceAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief ExecutiveRHEA-AIneutral
12/14/20 7:30 AMNasdaq : ATHA managementAthira Pharma Announces Appointment of Kelly A. Romano to its Board of DirectorsAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Directors.RHEA-AIneutral
12/08/20 7:30 AMNasdaq : ATHA clinical trialAthira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s DiseaseAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it has been awarded a research grant expected to total $15RHEA-AIneutral
12/01/20 7:30 AMNasdaq : ATHA clinical trialAthira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s DiseaseAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2RHEA-AIneutral
11/12/20 4:05 PMNasdaq : ATHA earningsAthira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights- LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, 2020 SEATTLE, Nov. 12, 2020RHEA-AIneutral
11/10/20 7:30 AMNasdaq : ATHA conferencesAthira Pharma to Present at Upcoming November Investor ConferencesAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer,RHEA-AIneutral
10/21/20 7:30 AMNasdaq : ATHA conferencesAthira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease TreatmentsAthira Pharma,RHEA-AIneutral
10/08/20 7:30 AMNasdaq : ATHA managementLumen Bioscience Announces Appointment of Dr. Mark Litton to Board of DirectorsLumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ: ATHA), to the company's Board ofRHEA-AIneutral
10/01/20 7:30 AMNasdaq : ATHA clinical trialAthira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's DiseaseAthira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronalRHEA-AIpositive
09/22/20 4:05 PMNasdaq : ATHA IPOofferingAthira Pharma Announces Closing of Initial Public OfferingAthira Pharma, Inc., (Nasdaq: ATHA) (“ Athira ”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the closing of its initial public offering ofRHEA-AIneutral